Immunopotentiative composition
AssigneesOno Pharmaceutical Co., Ltd., Tasuku Honjo
InventorsTasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
Life of this patent
Estimating the term…
Abstract
Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
Claims17
A method for treatment of a tumor in a patient, comprising administering to the patient a pharmaceutically effective amount of an anti-PD-1 monoclonal antibody.
A method for treatment of a melanoma in a patient, comprising administering to the patient a pharmaceutically effective amount of an anti-PD-1 monoclonal antibody.
Dependencies are inferred from the claim text.